• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Orencia (abatacept) powder for injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- August 2009

 

Summary View

 

ADVERSE REACTIONS

Clinical Experience in MTX-Naive Patients
  • Study VI was an active-controlled clinical trial in MTX-naive patients [see Clinical Studies (14.1)]. The safety experience in these patients was consistent with Studies I-V